Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(4.20)
# 1,535
Out of 4,692 analysts
81
Total ratings
48.6%
Success rate
16.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVCT Nuvectis Pharma | Initiated Coverage: Buy | n/a | $22.73 | - | 1 | Aug 24, 2026 | |
| VERA Vera Therapeutics | Maintained: Buy | $100 | $34.08 | +193.43% | 12 | Aug 10, 2026 | |
| NVAX Novavax | Maintained: Buy | $18 | $9.37 | +92.10% | 3 | Aug 6, 2026 | |
| ATAI AtaiBeckley | Downgraded: Hold | n/a | $7.34 | - | 1 | Jul 16, 2026 | |
| PMN ProMIS Neurosciences | Initiated Coverage: Buy | $40 | $13.07 | +204.13% | 1 | Jun 29, 2026 | |
| AXSM Axsome Therapeutics | Maintained: Buy | $220 → $272 | $198.52 | +37.01% | 5 | May 4, 2026 | |
| ALEC Alector | Upgraded: Buy | n/a | $2.26 | - | 3 | Apr 15, 2026 | |
| RZLT Rezolute | Maintained: Hold | n/a | $4.69 | - | 6 | Mar 25, 2026 | |
| ALKS Alkermes | Maintained: Buy | $43 | $46.99 | -8.49% | 1 | Mar 11, 2026 | |
| CRVO CervoMed | Initiated Coverage: Buy | n/a | $2.63 | - | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $11.76 | - | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $105.61 | n/a | 2 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.98 | n/a | 5 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.7114 | n/a | 6 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $71.73 | n/a | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $14.76 | n/a | 7 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $4.94 | n/a | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $1.10 | n/a | 8 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $3.45 | n/a | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 | $7.22 | n/a | 4 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $2.85 | n/a | 3 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $27.41 | n/a | 3 | Jun 23, 2023 |
Nuvectis Pharma
Aug 24, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $22.73
Upside: -
Vera Therapeutics
Aug 10, 2026
Maintained: Buy
Price Target: $100
Current: $34.08
Upside: +193.43%
Novavax
Aug 6, 2026
Maintained: Buy
Price Target: $18
Current: $9.37
Upside: +92.10%
AtaiBeckley
Jul 16, 2026
Downgraded: Hold
Price Target: n/a
Current: $7.34
Upside: -
ProMIS Neurosciences
Jun 29, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $13.07
Upside: +204.13%
Axsome Therapeutics
May 4, 2026
Maintained: Buy
Price Target: $220 → $272
Current: $198.52
Upside: +37.01%
Alector
Apr 15, 2026
Upgraded: Buy
Price Target: n/a
Current: $2.26
Upside: -
Rezolute
Mar 25, 2026
Maintained: Hold
Price Target: n/a
Current: $4.69
Upside: -
Alkermes
Mar 11, 2026
Maintained: Buy
Price Target: $43
Current: $46.99
Upside: -8.49%
CervoMed
Dec 18, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $2.63
Upside: -
Oct 15, 2025
Reiterated: Buy
Price Target: n/a
Current: $11.76
Upside: -
Aug 22, 2025
Reiterated: Buy
Price Target: n/a
Current: $105.61
Upside: n/a
Jul 10, 2025
Reiterated: Buy
Price Target: n/a
Current: $2.98
Upside: n/a
Jul 7, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.7114
Upside: n/a
Jul 2, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $71.73
Upside: n/a
Jul 1, 2025
Reiterated: Buy
Price Target: n/a
Current: $14.76
Upside: n/a
May 13, 2025
Reiterated: Buy
Price Target: n/a
Current: $4.94
Upside: n/a
Mar 3, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $1.10
Upside: n/a
Jan 10, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $3.45
Upside: n/a
Aug 8, 2023
Reiterated: Buy
Price Target: $34
Current: $7.22
Upside: n/a
Aug 8, 2023
Reiterated: Buy
Price Target: $13
Current: $2.85
Upside: n/a
Jun 23, 2023
Rated: Hold
Price Target: n/a
Current: $27.41
Upside: n/a